1-7 of 7
Ama Rohatiner
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Health-Related Quality of Life in Patients with Advanced-Stage Follicular Lymphoma Receiving Consolidation with 90 Y-Ibritumomab Tiuxetan (Zevalin®) of First Remission: Results from the Randomized Phase 3 First-Line Indolent Trial (FIT).

Kathleen Gondek, Sonalee Shah, Angelika Bischof-Delaloye, Ama Rohatiner, Gilles Salles, Barbara Putz, Michael Kunz, Anton Hagenbeek
Journal: Blood
Blood (2007) 110 (11): 3319.
https://doi.org/10.1182/blood.V110.11.3319.3319
Published: 2007
Journal Articles

Radioimmunotherapy with 90 Y-Ibritumomab Tiuxetan (Zevalin®) as Consolidation of First Remission in Patients with Advanced Stage Follicular Lymphoma: A ’Real-Time’ MBR RQ-PCR Analysis.

Lindsey Goff, Karin Summers, Sameena Iqbal, Jens Kuhlmann, Michael Kunz, Anton Hagenbeek, Andrew Lister, Ama Rohatiner
Journal: Blood
Blood (2007) 110 (11): 3412.
https://doi.org/10.1182/blood.V110.11.3412.3412
Published: 2007
Journal Articles

90 Y-Ibritumomab Tiuxetan (Zevalin®) Consolidation of First Remission in Advanced Stage Follicular Non-Hodgkin’s Lymphoma: First Results of the International Randomized Phase 3 First-Line Indolent Trial (FIT) in 414 Patients.

Anton Hagenbeek, Angelika Bischof-Delaloye, John A. Radford, Ama Rohatiner, Gilles Salles, Achiel Van Hoof, Barbara Putz, Michael Kunz, Franck Morschhauser
Journal: Blood
Blood (2007) 110 (11): 643.
https://doi.org/10.1182/blood.V110.11.643.643
Published: 2007
Journal Articles

Clinical Activity of the Immunoconjugate CMC-544 in B-Cell Malignancies: Preliminary Report of the Expanded Maximum Tolerated Dose (MTD) Cohort of a Phase 1 Study.

Luis Fayad, MD, Hemant Patel, PhD, Gregor Verhoef, MD, PhD, Myron Czuczman, MD, James Foran, MD, Eva Gine, MD, Ama Rohatiner, MD, Mitchell R. Smith, MD, Mark Shapiro, MD, PhD, Anjali Advani, MD
Journal: Blood
Blood (2006) 108 (11): 2711.
https://doi.org/10.1182/blood.V108.11.2711.2711
Published: 2006
Journal Articles

Preliminary Report of a Phase 1 Study of CMC-544, an Antibody-Targeted Chemotherapy Agent, in Patients with B-Cell Non-Hodgkin’s Lymphoma (NHL).

Anjali Advani, Eva Giné, Christian Gisselbrecht, Ama Rohatiner, Steven Rosen, Mitchell Smith, Joseph Boni, Chantal Lejeune, Hemant Patel
Journal: Blood
Blood (2005) 106 (11): 230.
https://doi.org/10.1182/blood.V106.11.230.230
Published: 2005
Journal Articles

Follicular Lymphoma International Prognostic Index

Clinical Trials & Observations
Philippe Solal-Céligny, Pascal Roy, Philippe Colombat, Josephine White, Jim O. Armitage, Reyes Arranz-Saez, Wing Y. Au, Monica Bellei, Pauline Brice, Dolores Caballero, Bertrand Coiffier, Eulogio Conde-Garcia, Chantal Doyen, Massimo Federico, Richard I. Fisher, Javier F. Garcia-Conde, Cesare Guglielmi, Anton Hagenbeek, Corinne Haïoun, Michael LeBlanc, Andrew T. Lister, Armando Lopez-Guillermo, Peter McLaughlin, Noël Milpied, Pierre Morel, Nicolas Mounier, Stephen J. Proctor, Ama Rohatiner, Paul Smith, Pierre Soubeyran, Hervé Tilly, Umberto Vitolo, Pier-Luigi Zinzani, Emanuele Zucca, Emili Montserrat
Journal: Blood
Blood (2004) 104 (5): 1258–1265.
https://doi.org/10.1182/blood-2003-12-4434
Published: 2004
Journal Articles

A feasibility study of simultaneous administration of gemtuzumab ozogamicin with intensive chemotherapy in induction and consolidation in younger patients with acute myeloid leukemia

Clinical Trials & Observations
William J. Kell, Alan K. Burnett, Raj Chopra, John A. L. Yin, Richard E. Clark, Ama Rohatiner, Dominic Culligan, Ann Hunter, Archie G. Prentice, Donald W. Milligan
Journal: Blood
Blood (2003) 102 (13): 4277–4283.
https://doi.org/10.1182/blood-2003-05-1620
Published: 2003